
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Experts in gynecological oncology review 3 clinical cases and best practices for various patients with newly diagnosed and recurrent ovarian cancer.






